A Phase 2, Randomized, Observer-Blind, Dose-Finding, Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults 65 Years and Older
Phase: PHASE2
Conditions: Pneumococcal Vaccines
Sponsor: Vaxcyte, Inc.

VAX24-102 
 
 
CLINICAL STUDY PROTOCOL:  A Phase 1/2a, Randomized, Observer-Blind, Dose-
Finding, Controlled, Clinical Study to Evaluate the 
Safety, Tolerability, and Immunogenicity of a 24-
Valent Pneumococcal Conjugate Vaccine (VAX-24) 
in Healthy Adults 65 Years and Older 
  
 
 
NCT IDENTIFIER:    
 
NCT05297578 
 
DOCUMENT DATE:   
 
31 May 2022